Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerGiorgio V. Scagliotti, David R. Gandara, Purvish Parikh et al.|Journal of Clinical Oncology|2008Cited by 3.2k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialRobert Pirker, U. Gatzemeier, Jose R. Pereira et al.|The Lancet|2009Cited by 1.4k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Luis Paz‐Ares, Miyoung Kim et al.|The Lancet Oncology|2016Cited by 1.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Geoffrey R. Oxnard et al.|New England Journal of Medicine|2020Cited by 835